Literature DB >> 1487481

The proper use of sleeping pills in the primary care setting.

W C Dement1.   

Abstract

Insomnia is a highly prevalent problem occurring in about 35% of the adult population. The complaint can be divided into temporary insomnia and persistent insomnia. A 1983 NIMH/OMAR Consensus Development Conference on drugs and insomnia issued guidelines for the use of sleep-promoting medications. There was a consensus that hypnotic medication is indicated for the treatment of temporary insomnia. Temporary insomnia, in response to external circumstances, is real and can have very serious consequences. This paper reviews the proper use of sleeping pills in the primary care setting in the context of current controversy involving benzodiazepines in general and benzodiazepine hypnotics in particular. It is concluded if the physician feels a patient's temporary insomnia warrants symptomatic relief with medication, it is appropriate to prescribe use of the lowest effective dose of a benzodiazepine hypnotic for several nights. Depending on the circumstances, the physician can specify either a short-acting or a long-acting hypnotic. The patient should be firmly instructed to call the clinic or office the next day to report results.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1487481

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  3 in total

Review 1.  The socioeconomic impact of insomnia. An overview.

Authors:  L A Chilcott; C M Shapiro
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 2.  Pharmacotherapy of insomnia: practice and prospects.

Authors:  J Dingemanse
Journal:  Pharm World Sci       Date:  1995-05-26

3.  An assessment of quality of sleep and the use of drugs with sedating properties in hospitalized adult patients.

Authors:  Luciana Frighetto; Carlo Marra; Shakeel Bandali; Kerry Wilbur; Terryn Naumann; Peter Jewesson
Journal:  Health Qual Life Outcomes       Date:  2004-03-24       Impact factor: 3.186

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.